• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article (55029660)   Find a Category (126)   Find a Journal (6150)   Find a Scholar (3940)   Find an Academic Assistant (17)
Find an Article PDF (4591707)   Today's Articles (379)   Subscriber (49313)
Citation(s) in RCA

Indexed Articles
Ranked By
Results Analysis
  •   
  •   
  •   
  •   
Results Analysis
Year Published
Show more   Refine
For: Smith S, Munoz J, Stevens D, Smith S, Feldman T, Ye J, de Vos S, Hess B, Miller C, Khatcheressian J, Birrell M, Leeds J, Coffey G, Conley P, Michelson G, Curnutte J, Hamlin P. RAPID AND DURABLE RESPONSES WITH THE SYK/JAK INHIBITOR CERDULATINIB IN A PHASE 2 STUDY IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA-ALONE OR IN COMBINATION WITH RITUXIMAB. Hematol Oncol 2019. [DOI: 10.1002/hon.30_2629] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Number Cited by Other Article(s)
1
Novel Agents Beyond Immunomodulatory Agents and Phosphoinositide-3-Kinase for Follicular Lymphoma. Hematol Oncol Clin North Am 2020;34:743-756. [DOI: 10.1016/j.hoc.2020.03.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
2
Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-Cell Lymphoma. Clin Cancer Res 2020;26:3546-3556. [DOI: 10.1158/1078-0432.ccr-19-3239] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2019] [Revised: 03/11/2020] [Accepted: 04/17/2020] [Indexed: 11/16/2022]
PrevPage 1 of 1 1Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA